Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. Mai 2014 08:00 ET | Quelle: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals' PSMA ADC Data Selected for Poster Highlight Presentation at ASCO 2014

TARRYTOWN, N.Y., May 30, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company that is developing innovative approaches to targeting and treating prostate cancer,...
09. Mai 2014 07:30 ET | Quelle: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Announces First Quarter 2014 Financial Results

TARRYTOWN, N.Y., May 9, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced its results of operations for the quarter ended March 31. Net loss for the quarter was...
01. Mai 2014 07:30 ET | Quelle: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Sets First Quarter 2014 Financial Results Call for May 9

TARRYTOWN, N.Y., May 1, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative ways to target and treat prostate cancer,...
24. April 2014 10:16 ET | Quelle: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Announces the Completion of Enrollment of Chemotherapy Naive Cohort in Phase II Trial of PSMA ADC

TARRYTOWN, N.Y., April 24, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) an oncology company focused on the development of innovative approaches to targeting and treating...
07. April 2014 12:00 ET | Quelle: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals CEO, Mark R. Baker, to Present at 13th Annual Needham Healthcare Conference

TARRYTOWN, N.Y., April 7, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company focused on the development of innovative approaches to targeting and treating...
01. April 2014 12:35 ET | Quelle: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications

TARRYTOWN, N.Y. and HAMILTON, Ontario, April 1, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), and Centre for Probe Development and Commercialization (CPDC) today announced...
13. März 2014 07:37 ET | Quelle: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2013 Financial Results and Initiates Clinical Development of Small Molecule Targeted Therapeutic

TARRYTOWN, N.Y., March 13, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced its results of operations for the fourth quarter and year-end 2013. The company also...
10. März 2014 13:47 ET | Quelle: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Sets 4Q and Year-End 2013 Financial Results Call for March 13

TARRYTOWN, N.Y., March 10, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative ways to target and treat prostate cancer,...
04. März 2014 12:00 ET | Quelle: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Sets 1Q 2014 Financial Results Call for March 13

TARRYTOWN, N.Y., March 4, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative ways to target and treat prostate cancer,...
21. Februar 2014 09:00 ET | Quelle: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

TARRYTOWN, N.Y., Feb. 21, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today the pricing of an underwritten public offering of 7,608,696 primary shares of its...

Vorherige Seite

Nächste Seite